Copyright
©2012 Baishideng.
World J Obstet Gynecol. Oct 10, 2012; 1(3): 35-39
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Table 3 Serious adverse events observed in the two Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie phase II studies using irinotecan + docetaxel or liposomal doxorubicin +/- gemcitabine + G-CSF in patients with platinum-resistant and platinum-refractory ovarian cancer n (%)
| Type of SAE | Weekly irinotecan + docetaxel (n = 15) | Liposomal doxorubicin +/- gemcitabine (n = 12) |
| Subileus and fatigue | 0 | 3 (25) |
| Uncontrollable vomiting and fever | 0 | 2 (17) |
| Febrile neutropenia | 0 | 1 (8) |
| Pulmonary embolism/deep pelvic vein thrombosis | 2 (13) | 1 (8) |
| Pneumonia | 0 | 1 (8) |
| Significant pleural effusion | 0 | 1 (8) |
| Mucositis/diarrhea | 1 (7) | 1 (8) |
| Generalized edema | 0 | 1 (8) |
| Total number of SAE | 3 (20) | 11 (91) |
- Citation: Petru E, Volgger B, Bogner G, Angleitner-Boubenizek L, Deibl M, Schauer C, Reinthaller A, Wolfram G, Zeimet AG, Marth C. Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies. World J Obstet Gynecol 2012; 1(3): 35-39
- URL: https://www.wjgnet.com/2218-6220/full/v1/i3/35.htm
- DOI: https://dx.doi.org/10.5317/wjog.v1.i3.35